The negative PFS result for the cancer vaccine drew disappointment, but the Phase II/III AHEAD-MERIT trial’s statistical plan ...

International weakness and an Abiomed slump weigh on the segment, while executives promise a better fourth quarter.

Eli Lilly’s oral GLP-1 contender orforglipron is among four new drugs up for marketing approval recommendations by the ...

This year’s resurgence in IPOs continues, but there are signs that investor enthusiasm for biotech has cooled in recent weeks ...

A further settlement of over $1m has been secured to compensate victims of an alleged US generic pricing inflation scheme ...

The newly appointed members of the European Medicines Agency’s New Approach Methodologies Operational Expert Group are drawn ...

OH and MGPI Schedule I controlled substances when either one alone, or combined, exceeds 1mg per gram in solid products or ...

LigIT.AI and Nutshell Therapeutics raise new funding for the development of oral cyclic peptides and allosteric drugs, ...

The LPA1 antagonist would add a new mechanism of action to idiopathic pulmonary fibrosis treatment if approved, but questions ...

Foghorn Therapeutics’s market cap fell below its cash following Eli Lilly’s exit and Sanofi hit a multi-year low after ...

Pharmaceutical companies need to give more clarity about what they would provide in return for higher drug prices.

Bausch + Lomb board chairman and Bausch Health CEO Thomas Appio has been appointed interim CEO effective immediately. Bausch ...